Stock Events

Stock Events

Biogen 

CL$181,400.00
507
+CL$0.00+0%Wednesday 13:30

Statistics

Day High
181,400
Day Low
181,400
52W High
250,820
52W Low
140,900
Volume
0
Avg. Volume
0
Mkt Cap
26.81T
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 28Expected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
999
2,176.37
3,353.74
4,531.12
Expected EPS
1,966.88250954
Actual EPS
2,586.9094

Financials

13.23%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
9.24TRevenue
1.22TNet Income

Analyst Ratings

$139,813.92Average Price Target
The highest estimate is ⁦164,978.90⁩.
From 22 ratings within the last 6 months. This is not an investment recommendation.
Buy
73%
Hold
23%
Sell
5%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIIBCL.SN. It's not an investment recommendation.
Apple
120
AAPL
Amazon
117
AMZN
Microsoft
114
MSFT
NVIDIA
102
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes directly with Biogen in the multiple sclerosis and spinal muscular atrophy markets.
Novartis
NVS
Mkt Cap303.67B
Novartis AG competes in the multiple sclerosis space with its drug Gilenya and in gene therapy for spinal muscular atrophy.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a broad portfolio that includes treatments in areas where Biogen is active, such as neurological disorders.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. competes in the area of neurodegenerative diseases, a key focus area for Biogen.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company is involved in Alzheimer's disease research and competes with Biogen's portfolio in neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. has a growing portfolio in neuroscience, directly competing with Biogen's core market.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. competes with Biogen in the broader biotech space, including treatments for neurological conditions.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. is expanding into the immunology and inflammatory disease market, areas of interest for Biogen.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical Industries Limited offers generic versions of multiple sclerosis drugs, directly competing with Biogen's branded products.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC has a diversified portfolio that includes new efforts in neurology and biologics, competing with Biogen's research and development focus.

About

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Show More
CEO
Christopher A. Viehbacher
Employees
7500
Country
United States
ISIN
US09062X1037
WKN
000789617

Listings

XNAS
US
BIIB
STU
DE
IDP.STU
BA
AR
BIIB.BA
MU
DE
IDP.MU

0 Comments

Share your thoughts

FAQs

What is Biogen stock price today?▼
The current price of BIIBCL.SN is CL$181,400.00 CLP — it has increased by +0% in the past 24 hours. Watch Biogen stock price performance more closely on the chart.
What is Biogen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Chilean Stock Exchange exchange Biogen stocks are traded under the ticker BIIBCL.SN.
Is Biogen stock price growing?▼
BIIBCL.SN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Biogen has showed a +28.74% increase.
What is Biogen market cap?▼
Today Biogen has the market capitalization of 26.81T
When is the next Biogen earnings date?▼
Biogen is going to release the next earnings report on February 17, 2027.
What were Biogen earnings last quarter?▼
BIIBCL.SN earnings for the last quarter are 2,586.91 CLP per share, whereas the estimation was 1,966.88 CLP resulting in a +31.52% surprise. The estimated earnings for the next quarter are N/A CLP per share.
What is Biogen revenue for the last year?▼
Biogen revenue for the last year amounts to 9.24T CLP.
What is Biogen net income for the last year?▼
BIIBCL.SN net income for the last year is 1.22T CLP.
How many employees does Biogen have?▼
As of November 8, 2026, the company has 7,500 employees.
In which sector is Biogen located?▼
Biogen operates in the Health & Wellness sector.
When did Biogen complete a stock split?▼
Biogen has not had any recent stock splits.
Where is Biogen headquartered?▼
Biogen is headquartered in CAMBRIDGE, United States.